The meeting was attended by over 900 participants, doctors and biomedical students from over 50 countries and featured 50 lectures and over 100 poster presentations. Sponsored by the Gulf Scientific Corporation, the meeting was organized into a series of nine themed sessions that covered: 1) cancer genomics and epigenetics;
2) genomic and epigenetic studies; 3) genomics of blood and metabolic disorders; 4) cytogenetic diagnosis and molecular profiling; 5) next generation sequencing; 6) consanguinity and hereditary diseases; 7) clinical genomics; 8) clinical applications of pharmacogenomics; and, 9) genomics in public health.
Opening Keynote
The opening Keynote lecture was given by Prof. David N. Cooper (Cardiff, UK) on the molecular basis of reduced (or incomplete) penetrance in inherited human disease. He discussed how reduced penetrance can be a function of factors such as specific mutation(s), allele dosage, differential allelic expression, copy number variation and the influence of additional genetic variants (in cis or in trans).
Studies of Arab populations
The Arab world comprises 22 countries and extends from Mauritania in the west to Oman in the east (Figure 1 Olaf Riess and Franz Schaefer, respectively, RD-CONNECT allows scientists to share data from their genomics research projects leading to faster diagnosis, better treatments and quality of life improvement for patients with rare diseases.
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Special medical issues in the Arab world
The conference highlighted some of the special medical issues in the Arab world such as increased homozygosity due to consanguinity, which is linked to a high overall risk of cancer. Dr. Lotfi Chouchane (Qatar) reported that breast cancer is the most common malignant disease in women from Arab populations comprising up to 42% of all tumors, and presenting 10 years earlier than in women from Western Europe (Chouchane et al, 2013) . It was also shown that triple negative breast cancer (i.e., any breast cancer that does not express the genes for estrogen receptor, progesterone receptor and Her2/neu) is more common in this part of the world. This data contrasts with the incidence of breast cancer in Europe and the USA, where the incidence has fallen in recent years.
Recessive disorders are highly prevalent in the UAE due to high rates of consanguinity among many of its subpopulations. However, the molecular causes underlying many of the rare recessive disorders are still unknown. Advances in NGS and bioinformatics have significantly expedited the discovery of the defective genes and mutations of many genetic conditions. Dr. Nadia Akawi (UAE) presented the UAE experience on the usage of WES for the identification of genes and mutations of several rare recessive disorders including those causing intellectual disability, macrocephaly, multiple dysplasia and distinctive facial appearance. Diagnoses were also obtained in heterogeneous cases of congenital muscular dystrophy with brain and eye anomalies, for camptodactyly-arthropathy-coxa vara-pericarditis syndrome (Akawi et al, 2012) .
A poster by Amal Al hashem and colleagues presented a study of 19,165 births in a Saudi population that showed that consanguinity is an independent risk factor for the high rate of birth defects in a population with a high rate of consanguineous marriages (Saadallah and Rashed, 2007) . Consanguinity has a statistically significant contribution in cases of genetic syndromes, and isolated renal defect. However, consanguinity has no statistically significant contribution in cases of chromosomal aberrations, isolated congenital heart disease and multiple malformations. 
Pharmacogenomics
Pharmacogenomics holds promise to rationalize drug use by increasing drug efficacy and minimizing drug toxicity. In developing countries, pharmacogenomics can also contribute towards reducing healthcare expenditure at a national level. Prof. George Patrinos (Greece) presented preliminary data indicating that there are significant differences among various European populations regarding pharmacogenomic biomarkers allele frequencies that can be readily applicable to rationalize drug use in these countries (Mette et al., 2012) . Also, he presented data from whole genome sequence analysis of 482 unrelated individuals of various ethnic backgrounds to obtain their personalized pharmacogenomic profiles, indicating that a significant number of novel pharmacogenomically relevant variants can be identified using this approach (Mizzi et al, submitted) . Also, these findings were replicated in a 7-member family of Greek origin in an effort to explain the variable response rate to acenocoumarol treatment in two family members. Overall, these data demonstrate that whole genome sequencing is necessary to accurately determine an individual's pharmacogenomics profile.
Additional clinical applications of pharmacogenomics were illustrated by Prof.
Ron van Schaik, who described the work at his laboratory. 
Large-scale sequencing projects
Another theme running through the conference was how to implement largescale sequencing projects on very large groups. The largest of these initiatives is "The Million Human Genomes Project" launched in November 2011 by Beijing Genomics Institute (BGI; http://www.genomics.cn) to decode the genome of over 1 million people. illustrated the benefit and advantages of nanoarrays for sequencing at several terabases per day per instrument (Drmanac et al, 2010) .
Genomics into Healthcare
The conference highlighted a number of issues at the interface of genomics and healthcare and the importance of NGS. Prof. Hilger Ropers (Germany) discussed intellectual disability (ID) and presented a novel diagnostic tool that utilizes WES and a proprietary algorithm to detect mutations in most of the presently known ID genes. This work is based on a previously described test for ~600 severe recessive childhood disorders (Bell et al, 2010) and on a comprehensive list of genes implicated in ID.
Furthermore, he anticipated that the technology will shed light on the molecular causes of ID and related conditions such as autism, schizophrenia and epilepsy, which are still largely unknown.
Prof. Maurizio Ferrari (Italy) showed his work with 91 patients that resulted in the identification of novel variants which could be critical for improving risk stratification and clinical management of asymptomatic patients with Brugada syndrome. The predisposition for these patients to develop fatal arrhythmias cannot be easily predicted and no anti-arrhythmic drug is effective in preventing these life-threatening arrhythmias. 
Closing Keynote
The meeting closed with a keynote speech by Prof. Angela Brand (The Netherlands) on "Genomics in Public Health". She stressed the need to change our perspective from diseases to diseasomes, risk factor to risk pattern, clinical utility to personal utility, and from complex disorders to multiple rare diseases (Brand, 2012) . This is in line with P4 Medicine (predictive, personalized, preemptive and participatory) and the anticipated era of precision medicine (Hood and Flores, 2012 ). Dr. Brand described public health genomics (PHG), the area of public health ensuring that scientific advances in genomics are effectively and responsibly translated into health policies and practices for the benefit of population health, and the connected activities needed for its implementation (Brand, 2012) . Her Institute aims to fulfill this task for European Member
States via the European Centre for Public Health Genomics (ECPHG).
Conclusions
The joint 
